(Axios) – Hospitals within months could get extra federal money to administer pricey new gene therapies for sickle cell disease, including the first CRISPR-based treatment. Why it matters: The Medicare proposal would provide more incentive to offer the multimillion-dollar gene therapies when about half of those living with sickle cell are lower-income people on Medicaid. (Read More)